Tag: GlobeNewswire

Central Bank of Savings Banks Finland Plc, Sp Mortgage Bank Plc & Savings Banks Group

Stock Exchange Release
3^rd of November 2026 at 8 am (CET +1)

Central Bank of Savings Banks Finland Plc and Sp Mortgage Bank Plc will publish their Board of Directors Report 2026 on 11^th of February 2027. Savings Banks Group will publish their Releases of Financial Statements for 2026 at the same time on 11^th of February 2027 All will be published as a stock exchange release and can be also found at www.saastopankki.fi.

CENTRAL BANK OF SAVINGS BANKS FINLAND PLC, SP MORTGAGE BANK PLC & SAVINGS BANKS GROUP

Further information:

Kai Koskela
CEO
Savings Banks’ Union Coop
+358 40 549 0430  
kai.koskela@saastopankki.fi

Central Bank of Savings Banks Finland Plc belongs to the Savings Banks Amalgamation. The role of the Central Bank of Savings Banks Finland Plc is to ensure the liquidity and borrowing activities of the Savings Banks Group. It acquires funds and operates in the money markets and capital markets on behalf of the Group as well as manages payment transfers. The Central Bank also manages the internal balancing of the Group’s liquidity.

//

Sp Mortgage Bank Plc is part of the Savings Banks Group and the Savings Banks Amalgamation. The role of Sp Mortgage Bank is, together with Central Bank of Savings Banks Finland Plc, to be responsible for obtaining funding for the Savings Banks Group from money and capital markets. Sp Mortgage Bank is responsible for the Savings Banks Group’s mortgage-secured funding by issuing covered bonds. 

POCASSET, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder and the global leader in autonomous seapower, and Thales, a global leader in advanced technologies, have successfully demonstrated an end-to-end autonomous mine countermeasure capability.

This demonstration leveraged Thales’ Expeditionary Pathmaster, an open and modular expeditionary mine countermeasure architecture designed to integrate autonomous platforms, sensors, mission management systems and effectors from multiple providers into a unified operational framework.

Through this architecture, HII’s REMUS 620 unmanned underwater vehicle (UUV), alongside sensors, mission management tools and neutralization capabilities from multiple providers, was integrated into a single end-to-end operational workflow spanning mine detection, classification and neutralization.

Photos accompanying this release are available at: https://www.hii.com/news/hii-and-thales-successfully-demonstrate-expeditionary-pathmasters-ability-to-deliver-an-end-to-end-autonomous-mine-countermeasure-mission.

The demonstration was conducted using Thales’ Expeditionary Portable Operation Center (ePOC), a rapidly deployable command and control system designed to support expeditionary mine warfare operations. Acting as the operational hub, the ePOC hosted Thales’ Mission Management System and sonar data analysis software, integrated with HII’s REMUS 620 UUV, HII’s Odyssey mission management solution and Thales’ Advanced Acoustic Concepts’ ANGLER mine neutralization capability.

The REMUS 620 is HII’s next-generation medium-class UUV, designed for long-range, multi-day operations with a modular, open architecture that enables the integration of mission-specific payloads and sensors. HII’s Odyssey Mission command and control enable mission planning and management, while supporting increasingly collaborative operations across unmanned platforms.

Together, these technologies demonstrated a complete “Find, Fix, Finish” mission chain of mine countermeasure operations:

• FIND: HII REMUS 620 UUV, integrated with the Thales SAMDIS 600 multi-aspect sonar, autonomously searches the undersea environment to detect potential mine threats, controlled by HII’s command and control (C2) software which interfaces with the Thales ePOC.
• FIX: Detected contacts were analyzed using Thales’ software, which combines high-resolution multi-aspect sonar imagery with AI-enabled Automatic Target Recognition (ATR) capabilities, enabling operators to classify and localize mine-like objects, thus building the tactical picture required for operational decision-making.
• FINISH: Thales AAC’s ANGLER underwater effector and Remotely Operated Vehicle (ROV) concluded the mission chain by completing rapid re-acquisition of the mine-like objects, visual identification of the mine threat, ultimately providing the means to engage and neutralize the identified mine.

All mission assets were successfully coordinated through the Expeditionary PathMaster environment, leveraging Thales’ mission management system within ePOC to provide operators with a unified operational picture and consistent command and control throughout the mission.

The demonstration included the automated launch and recovery of the REMUS UUV, equipped with Thales’ SAMDIS 600 Multi-Aspect Synthetic Aperture Sonar, using HII’s Sea Launcher system.

The exercise also highlighted Expeditionary PathMaster’s open architecture, which enabled Thales to integrate HII’s autonomous underwater systems and ANGLER’s neutralization capability into a common, NATO-compliant mission environment. This approach allows allied navies to combine capabilities from multiple suppliers while maintaining operational coherence.

“Bringing “Find, Fix and Finish” together demonstrates what is possible when proven unmanned platforms, advanced sensors, autonomy and effectors are designed to operate as an integrated system,” said Duane Fotheringham, president of HII’s Unmanned Systems group. “This demonstration advances our work with Thales from sensor integration to a complete mine countermeasure mission capability. Together, we are giving naval forces a path to conduct these demanding missions faster, at greater scale and with sailors farther from the mine threat.”

Building on HII and Thales’ successful 2025 integration and field exercise of the SAMDIS 600 sonar aboard the REMUS 620, the latest demonstration expanded beyond sensor integration and underwater performance to encompass mission management, AI-assisted exploitation and mine neutralization within a unified system.

Sébastien Guérémy, vice-president, Underwater Systems, Thales stated, “This demonstration alongside HII, a leading American partner, illustrates Thales’ ability to work with the best international players to address the critical challenges of mine warfare. Thales’ mine countermeasures solutions, such as Expeditionary PathMaster, has again proven that it can integrate autonomous platforms, advanced sensors, mission management and neutralization systems into a single AI-powered operational framework.”

As threats and mission requirements evolve, this demonstration underscores HII and Thales’ shared commitment to modular, interoperable and autonomous solutions that allow naval customers to rapidly integrate new sensors, platforms, autonomy and effectors.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.

The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

About Thales in the U.S. 

For more than a century, Thales has delivered proven, trusted and secure solutions to customers across the United States. The company brings a strong national footprint and a deeply skilled workforce dedicated to anticipating and exceeding customer needs. Backed by extensive manufacturing capabilities, Thales works closely with customers and local industries to solve complex challenges for every operational environment.   

About HII

HII is America’s Seapower Company. The nation’s largest shipbuilder, HII builds the manned and unmanned maritime systems and all-domain mission technologies that project U.S. and allied power around the world. With a more than 140-year history of advancing U.S. national security, HII is headquartered in Virginia and employs 45,000 people across three divisions. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact HII: 
Greg McCarthy
+00 (1) 202 264 7126
gregory.j.mccarthy@hii-co.com

Contacts Thales: 
Camille Heck
+33 (0)6 73 78 33 63
camille.heck@thalesgroup.com

Jennifer Tumminio
+00 (1) 571 969 0730
Jennifer.tumminio@thalesgroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f952abe-b254-49aa-b978-d2ccfa7db206

Approval underscores confidence in Biotalys’ AGROBODY® technology and follows strong interest from Dutch growers to test the product against fungal diseases in cucumber, tomato and strawberry

Ghent, BELGIUM, Nov. 03, 2026 (GLOBE NEWSWIRE) —          Press Release

Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announced that it has received approval from the Dutch Board for the Authorisation of Plant Protection Products and Biocides* to conduct large-scale demonstration trials of its next-generation biofungicide candidate, EVOCA NG, marking the world-first commercial application of the product under real growing conditions.

The approval by the Dutch regulatory authority enables commercial trials by growers on up to 150 hectares of tomatoes, 150 hectares of cucumbers, and 50 hectares of strawberries, significantly expanding the scale of Biotalys’ demonstration program running in previous years with the company’s first-generation biocontrol, EVOCA.

“The approval of this demonstration program marks an important milestone for our company,” said Carlo Boutton, Chief Executive Officer of Biotalys. “By enabling growers to evaluate EVOCA NG across larger commercial acreages while allowing harvested produce into the food chain, these trials provide real-world validation of our first commercial product as we continue to advance its development and production optimisation. It also reflects the growing confidence regulators have in the safety and potential of our AGROBODY based biofungicide technology.”

The trials will evaluate EVOCA NG for the control of both Botrytis and powdery mildew, two economically important fungal diseases affecting many crops worldwide. Botrytis can infect flowers, fruits, leaves and stems, causing tissue decay and grey mould that can reduce both crop yield and marketable quality. Powdery mildew develops mainly on the surface of leaves and other green tissues, where it can weaken plant growth, ultimately affecting crop productivity and fruit quality. By controlling these fungal pathogens, EVOCA NG supports growers in maintaining the yield and quality of their crops at a time when many conventional crop protection products face resistance, are being phased out or are no longer authorised.

Grower perspectives

Feedback from Dutch growers who used EVOCA in earlier demonstration trials in the Netherlands underscores the practical value of evaluating the technology under commercial growing conditions. “We applied EVOCA on 3.7 hectares of strawberries with great results,” said Noud Dings of Brookberries, where Biotalys’ product replaced a synthetic fungicide in a rotation program. Rob van Enckevort of De Peelkroon commented: “For a second year in a row, we successfully used EVOCA against powdery mildew in strawberries.”

Both growers also showed interest in the newly approved demonstration trials with EVOCA NG, which aim to familiarize farmers facing a shrinking crop protection toolbox with Biotalys’ new technology and support early product adoption ahead of its expected European registration and launch in 2029.

*Ctgb: College voor de toelating van gewasbeschermingsmiddelen en biociden.

About EVOCA NG

EVOCA® NG is Biotalys’ next-generation protein-based biofungicide candidate, developed using the Company’s proprietary AGROBODY® technology platform. The product is being developed to help fruit and vegetable growers effectively control the key fungal diseases Botrytis (grey mold) and powdery mildew while supporting increasingly sustainable agricultural production systems. EVOCA NG is expected to be Biotalys’ first commercial biofungicide, with a planned launch in the U.S. and E.U. in 2029, targeting a combined market of around USD 1.1 billion¹.

EVOCA NG has the same bioactive ingredient as EVOCA, the first-generation product that received EPA approval in the U.S. in December 2025 and state approval in Florida and California in 2026 and for which regulatory review is ongoing in the E.U. An approval of EVOCA paves the way for the regulatory submission of EVOCA NG, the product’s next generation version.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY® technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Investor Relations & Communications
T: +32 (0)9 274 54 00
E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website.

This announcement contains statements which are “forward-looking statements” or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, ‘believe’, ‘estimate’, ‘anticipate’, ‘expect’, ‘intend’, “have the potential”, ‘may’, ‘will’, ‘plan’, ‘continue’, ‘ongoing’, ‘possible’, ‘predict’, ‘plans’, ‘target’, ‘seek’, ‘would’ or ‘should’ or are evidenced by a date in the future, and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys’ actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

---

¹ Source: Kynetec 2020; Biotalys

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

THIRD QUARTER/NINE MONTHS | 2026

• Q3 2026 sales increased by 5.6 % in local currencies¹ to CHF 968.8 million, with positive pricing and volumes in Care Chemicals and Adsorbents & Additives, while Catalysts’ volumes remain impacted by Middle East conflict
• Q3 2026 EBITDA margin before exceptional items decreased by 230 basis points to 15.6 % as continued improvement in Adsorbents & Additives was more than offset by two effects of broadly similar magnitude. First, Corporate costs had a positive phasing effect from prior year that normalized in the current year. Second, Care Chemicals and Catalysts saw a less favorable mix and volatile raw materials that affected costs and valuation of inventory
• 9M 2026 sales increased by 1 % in local currencies to CHF 2 828.1 million, driven by positive pricing with resilient volumes
• 9M 2026 EBITDA margin before exceptional items of 17.1 % versus 18.0 % in the prior year as margin improvement in Care Chemicals and Adsorbents & Additives was more than offset by the Middle East impact on Catalysts
• Free cash flow conversion improved by 9 percentage points to 48 % (LTM), achieved through improved operating cash flow, disciplined capex, and effective net working capital management
• Contributions from performance improvement programs delivered CHF 79 million run-rate cost savings year to date (Q3 2026: CHF 10 million), on track to deliver full CHF 90 million in 2026
• Guidance for 2026 remains unchanged with strong order book into end of the year

“In the third quarter of 2026, Clariant delivered strong local currency sales growth of 5.6 %, demonstrating the effectiveness of our price management and the resilience of our portfolio in a volatile operating environment. Care Chemicals and Adsorbents & Additives recorded pricing-led growth, while Catalysts’ volumes remained impacted by the Middle East conflict. Our Group EBITDA margin before exceptional items of 15.6 % reflects an improvement in Adsorbents & Additives, which was more than offset by two effects of broadly similar magnitude: a one-off year-on-year impact from the phasing of provisions in Corporate costs, and the combined impact of a less favorable mix and of volatile raw materials on cost and inventory valuation in Care Chemicals and Catalysts. Effective working capital management and disciplined capital expenditure improved free cash flow conversion by 9 percentage points to 48 % for the last twelve months, up from 39 % in the prior year,” said Conrad Keijzer, Chief Executive Officer of Clariant.

“Our full year 2026 guidance remains unchanged, supported by a strong order book, particularly in Catalysts, for the fourth quarter and continued momentum in our performance improvement programs, which remain on track to deliver CHF 90 million in run-rate savings for 2026 and the full CHF 100 million by 2027. While inflationary pressures in raw materials, energy and logistics remain a challenge, our global production network and proven pricing capabilities position us well to protect margins as we close out the year,” Conrad Keijzer added.

Business Summary

Third Quarter					First Nine Months
in CHF million	2026	2025	% CHF	% LC(1)	2026	2025	% CHF	% LC(1)
Sales	968.8	905.9	6.9	5.6	2 828.1	2 886.6	– 2.0	1.0
EBITDA	144.0	158.8	– 9.3		444.2	449.9	– 1.3
– margin	14.9 %	17.5 %			15.7 %	15.6 %
EBITDA before exceptional items	151.5	162.0	– 6.5		482.8	520.9	– 7.3
– margin	15.6 %	17.9 %			17.1 %	18.0 %
Sales bridge:	Price 5.7 %; Volume – 0.1 %; Scope 0 %; Currency 1.3 %				Price 2.2 %; Volume – 1.2 %; Scope 0 %; Currency – 3.0 %

⁽¹⁾ Excluding price impact from hyperinflation country Türkiye

¹ All references to local currency growth, pricing, volumes, and scope exclude the price impact from hyperinflation country Türkiye. Currency translation impact includes the price impact from hyperinflation country Türkiye.

Third Quarter 2026 Group Discussion

MUTTENZ, 3 NOVEMBER 2026

Clariant, a sustainability-focused specialty chemical company, today announced third quarter 2026 sales of CHF 968.8 million, representing an increase of 5.6 % in local currency versus Q3 2025. When excluding the impact of portfolio pruning, sales in local currency increased by 6.7 %. Pricing was up 5.7 %, with increases in all business units in response to inflationary raw material, energy, and logistics costs. Volume increased by 1.0 % excluding the impact of portfolio pruning (- 0.1 % when included). In Swiss francs, sales were 6.9 % higher versus Q3 2025, with the positive currency impact of 1.3 % mainly driven by the Chinese yuan, Brazilian real, and the US dollar.

Care Chemicals sales increased by 6.6 % in local currency versus Q3 2025 and by 8.7 % when excluding the impact of portfolio pruning. Pricing was up 6.5 % with volumes modestly up (0.1 %) and 2.1 % growth excluding pruning. Sales grew in the industrial businesses (Industrial Applications, Mining Solutions and Base Chemicals) and in Personal & Home Care. Sales in Crop Solutions were flat, while Oil Services sales were lower due to the pruning measures and the Middle East impact. Catalysts’ sales increased by 1.8 % in local currency, as positive pricing of 3.7 % offset the volume decline of 1.9 %. The business saw a continued impact from the ongoing volatile situation in the Middle East, which led customers to delay orders. Sales grew in Propylene against a low comparable base, while other segments declined. Adsorbents & Additives sales increased by 6.4 % in local currency, with positive pricing of 5.4 % and volume growth of 1.0 %. Sales increased strongly in Additives, driven by both pricing and volume growth, while sales in Adsorbents increased modestly as growth in the Americas was more than offset by softer demand in Europe and APAC.

Group EBITDA before exceptional items of CHF 151.5 million decreased by 6.5 % year on year, with a corresponding margin of 15.6 % compared to 17.9 % in the prior year, which was positively impacted by a phasing of provisions in Corporate costs. The 230-basis point decrease reflects the normalization of this effect, coupled with the low operating leverage in Catalysts as well as mix and effects of volatile raw materials on costs and valuation of inventory in Care Chemicals and Catalysts. Benefits from the performance improvement programs supported margins, particularly in Adsorbents & Additives, while higher year-on-year prices for raw materials (12.0 %), energy (9.0 %) and logistics (23.7 %) were largely offset by pricing.

Key measures to deliver the targeted CHF 100 million performance improvement programs by 2027 are being implemented and cumulatively contributed CHF 79 million as of 30 September 2026. These include announced headcount reductions and procurement savings, in addition to the closure of two sites and two production lines in 2025. As a result, total cost savings in the third quarter of approximately CHF 10 million contributed positively to offset inflation. Restructuring charges of CHF 6 million related to these savings programs were booked during the quarter.

Group reported EBITDA decreased by 9.3 % to CHF 144.0 million, and the EBITDA margin of 14.9 % decreased by 260 basis points compared to the 17.5 % reported in the third quarter of 2025. Higher restructuring charges compared to the prior year contributed to this decline.

First Nine Months 2026 Group Discussion

In the first nine months of 2026, sales of CHF 2 828.1 million were up 1.0 % in local currency and 2.1 % when excluding the impact of portfolio pruning. Pricing had a positive impact on the Group of 2.2 %, while volumes slightly declined by 1.2 %, impacted by the Middle East conflict and portfolio pruning. Excluding portfolio pruning, volumes were flat at – 0.1 %. In Swiss francs, sales were 2.0 % lower versus the first nine months of 2025, with a negative currency impact of 3.0 % mainly driven by the Indian rupee, the US dollar, and the Euro.

Care Chemicals sales increased by 2.1 % in local currency and 4.3 % when excluding the pruning impact, with growth in Industrial Applications, Personal & Home Care, Mining Solutions, and Base Chemicals. Oil Services increased on an underlying basis when excluding the pruning impact, while sales declined in Crop Solutions. In Catalysts, sales decreased by 5.1 % in local currency, driven by lower volumes as the Middle East conflict led to delays in customer orders, particularly in the region and in Asia. Sales were lower in all segments except Specialties. Adsorbents & Additives sales increased by 3.0 % in local currency, driven by strong growth in Additives offsetting softer Adsorbents EMEA sales while Adsorbents APAC and Americas were flat.

Group EBITDA before exceptional items decreased by 7.3 % to CHF 482.8 million against the prior year, with the corresponding margin of 17.1 % vs. 18.0 % recorded in the prior year. Margin increases in Care Chemicals and Adsorbents & Additives were more than offset by Catalysts, where lower volumes impacted operating leverage. Higher raw materials (+ 4.0 %), energy costs (+ 5.7 %), and logistics costs (+ 6.2 %) were largely offset by pricing. The delivery of the performance improvement programs resulted in cost savings of CHF 79 million in the first nine months of 2026, underpinning expected run-rate savings of CHF 90 million for the year vs. CHF 50 million in the prior year.

Reported EBITDA for the Group decreased by 1.3 % to CHF 444.2 million despite lower restructuring costs compared to the prior year. The EBITDA margin of 15.7 % improved by 10 basis points from the 15.6 % reported for the same period in 2025.

At the end of the first nine months of 2026, the free cash flow conversion (LTM, October 2025 to September 2026) increased to 48 % from 39 % reported at the end of Q3 2025, driven mainly by improved operating cash flow, disciplined capex spending, and effective net working capital management.

Innovation and sustainability

Clariant’s digital catalyst monitoring platform, CLARITY™, and its AI-powered evolution, CLARITY™ Prime, received the “Best Digital Innovation” at the ICIS Innovation Awards 2026. The platform allows Clariant to provide customers with real-time insights into their plants, greatly improving technical support and decision-making capabilities. CLARITY™ is available in 8 languages and spans 250+ plants, 100+ companies, and 800+ customers in 42 countries, covering 22 processes across oxidation, hydrogenation, petrochemicals, and syngas and hydrogen applications, while the paid add-on service CLARITY™ Prime combines machine learning with first-principles process engineering and is calibrated to individual plant configurations.

Clariant was awarded a first-fill contract to supply its CATOFIN™ catalyst and Heat Generating Material (HGM) for the world’s largest licensed propane dehydrogenation (PDH) unit with a capacity of 1.2 million metric tons per annum, being constructed by Zhejiang Petroleum & Chemical Co., Ltd. (ZPC) in Zhejiang Province, China. CATOFIN is a joint offering from Clariant and Lummus that delivers outstanding propylene yields, reliability, and cost efficiency, backed by over 60 years of continuous improvement and with over 40 projects awarded since 2017.

Clariant also made a significant advance in enhancing its local footprint in China with the opening of two new R&D laboratories for its Additives business. This enables the company to accelerate innovation, keep pace with fast-moving market trends, respond more closely to customer needs in China and across Asia Pacific, and extend new solutions to global markets with greater speed and competitiveness. The new laboratories have the capabilities to fully develop new additives, such as next generation flame retardant products, antioxidants, light stabilizers and waxes, entirely within China.

Clariant’s Lucas Meyer Cosmetics business delivered its latest successful innovation to the market with the global launch of KanuFresh™, a 100 % natural-origin active ingredient responsibly sourced from Australian kanuka leaves. This solution delivers long-lasting control of visible signs of perspiration, odor and irritation through a unique multi-action mechanism. The ingredient is supported by a robust package of in vitro and in vivo studies, alongside clinical validation in real-world conditions. KanuFresh™ is readily biodegradable, produced using 100 % renewable energy and made with responsibly sourced raw materials.

Overall, Clariant’s strategic focus on innovative chemistry was reflected with an increase in innovation sales to 19.0 % for the last twelve months (LTM, October 2025 to September 2026), up from 18.8 % in the full year 2025.

Clariant’s Scope 1 and 2 total greenhouse gas emissions were 2.3 % lower at 0.42 million metric tons in the last twelve months (LTM, October 2025 to September 2026), compared to 0.43 million metric tons in the full year 2025. The total indirect greenhouse gas emissions for purchased goods and services (Scope 3.1 and 3.12 emissions) declined by 3.5 % to 3.60 million metric tons in the last twelve months, compared to 3.73 million metric tons in the full year 2025.

Guidance remains unchanged

For the full year 2026, Clariant expects continued challenging and volatile market conditions with geopolitical challenges, uncertainties, and risks. The conflict in the Middle East will continue to impact orders in Catalysts and Oil Services (Care Chemicals). Clariant continues to drive its proven value-based price management in order to mitigate the significant annualized cost inflation in raw material, energy, and logistics costs, supported by its global production network.

The company continues to expect sales in local currency to be around flat as it looks to offset a negative top-line impact for the Group of 1 % (2 % in Care Chemicals) from portfolio pruning in the prior year. Growth is expected in Adsorbents & Additives with slight underlying growth in Care Chemicals, while sales in Catalysts are expected to be below the levels of 2025.

Clariant expects an EBITDA margin before exceptional items of around 18 % in 2026. This is supported by the strong order book, particularly in Catalysts, for the final quarter of 2026 and successful implementation of performance improvement programs, which are expected to deliver CHF 90 million run-rate savings for the year 2026. In 2027, Clariant expects to complete the CHF 100 million programs. Clariant expects to achieve a free cash flow conversion of above 45 % in 2026.

Clariant remains committed to the delivery of its medium-term targets, to be achieved by 2027 at the latest.

Business Discussion

Business Unit Care Chemicals

Third Quarter					First Nine Months
in CHF million	2026	2025	% CHF	% LC(1)	2026	2025	% CHF	% LC(1)
Sales	531.8	490.6	8.4	6.6	1 582.1	1 586.4	– 0.3	2.1
EBITDA	92.0	93.0	– 1.1		302.4	276.9	9.2
– margin	17.3 %	19.0 %			19.1 %	17.5 %
EBITDA before exceptional items	93.0	93.3	– 0.3		311.8	310.2	0.5
– margin	17.5 %	19.0 %			19.7 %	19.6 %
Sales bridge:	Price 6.5 %; Volume 0.1 %; Scope 0 %; Currency 1.8 %				Price 2.2 %; Volume – 0.1 %; Scope 0 %; Currency – 2.4 %

⁽¹⁾ Excluding hyperinflation accounting country Türkiye

Sales

In the third quarter of 2026, sales in the Business Unit Care Chemicals increased by 6.6 % in local currency and by 8.7 % when excluding the impact of portfolio pruning. Pricing was up 6.5 %, reflecting increased formula-based prices and the continued successful implementation of value-based pricing to offset inflationary input costs due to the conflict in the Middle East. Volumes were flat (0.1 %) when including the impact of the portfolio pruning measures. When excluded, volumes grew by 2.1 %. Sales in Swiss francs increased by 8.4 % versus Q3 2025.

Growth was driven by the industrial businesses (Industrial Applications, Mining Solutions and Base Chemicals) and Personal & Home Care, with positive pricing and higher volumes. Sales in Crop Solutions were flat, while Oil Services sales were lower due to the pruning measures and Middle East impact.

Care Chemicals sales in the Europe, Middle East & Africa region increased at a high-single-digit percentage rate, driven by Mining Solutions and Crop Solutions. In the Americas, sales increased by a mid-single-digit percentage rate, as strong growth in Industrial Applications and Personal & Home Care more than offset lower sales in Crop Solutions and Oil Services that included portfolio pruning. Sales in Asia-Pacific increased at a high single-digit percentage rate, driven by Industrial Applications, Personal & Home Care, and Base Chemicals.

In the first nine months of 2026, sales in the Business Unit Care Chemicals increased by 2.1 % in local currency and by 4.3 % excluding the impact from portfolio pruning. Pricing increased by 2.2 %, while volumes were broadly flat (- 0.1 %) including portfolio pruning and grew by 2.1 % when excluded. Industrial Applications showed the strongest growth, followed by Mining Solutions and Personal & Home Care. In Swiss francs, sales decreased by 0.3 %.

EBITDA Margin

In the third quarter, EBITDA before exceptional items slightly decreased by 0.3 % to CHF 93.0 million, representing a margin of 17.5 % compared to 19.0 % in the prior year. The 150 basis-point decline versus the prior year was the result of less favorable business mix and the effects of volatile raw materials on costs and valuation of inventory..

The reported EBITDA of CHF 92.0 million decreased by 1.1 % compared to the prior year. The corresponding reported EBITDA margin of 17.3 % decreased by 170 basis points versus 19.0 % in the prior year.

For the first nine months of 2026, EBITDA before exceptional items slightly increased by 0.5 % to CHF 311.8 million with the corresponding margin improving to 19.7 % from 19.6 % in the prior year. Reported EBITDA increased to CHF 302.4 million from CHF 276.9 million, with the corresponding margin improving by 160 basis points to 19.1 % from 17.5 %, driven by lower restructuring costs.

Business Unit Catalysts

Third Quarter					First Nine Months
in CHF million	2026	2025	% CHF	% LC(1)	2026	2025	% CHF	% LC(1)
Sales	173.3	171.0	1.3	1.8	492.1	551.2	– 10.7	– 5.1
EBITDA	23.3	32.5	– 28.3		63.2	104.1	– 39.3
– margin	13.4 %	19.0 %			12.8 %	18.9 %
EBITDA before exceptional items	23.1	32.7	– 29.4		68.7	107.7	– 36.2
– margin	13.3 %	19.1 %			14.0 %	19.5 %
Sales bridge:	Price 3.7 %; Volume – 1.9 %; Scope 0 %; Currency – 0.5 %				Price 1.6 %; Volume – 6.7 %; Scope 0 %; Currency – 5.6 %

⁽¹⁾ Excluding hyperinflation accounting country Türkiye

Sales

In the third quarter of 2026, sales in the Business Unit Catalysts increased by 1.8 % in local currency and by 1.3 % in Swiss francs. While pricing was up by 3.7 %, volumes declined by 1.9 % versus Q3 2025 due to an ongoing significant impact from the Middle East conflict.

Sales in Propylene more than doubled against a very low comparison base. Specialties were flat, sales in Ethylene decreased at a double-digit percentage rate, and sales in Syngas & Fuels decreased at a low-single-digit percentage rate.

Catalysts’ sales in the Europe, Middle East & Africa region grew at a mid-single-digit percentage rate driven by Syngas & Fuels and Propylene. In the Americas region, sales declined at a mid-twenties percentage rate due to the project nature of the business in Specialties and Syngas & Fuels. In Asia-Pacific, the largest geographic market, sales grew at a double-digit percentage rate driven by Specialties and Ethylene offsetting declines in Propylene and Syngas & Fuels.

In the first nine months of 2026, sales in the Business Unit Catalysts decreased by 5.1 % in local currency and by 10.7 % in Swiss francs. Positive pricing of 1.6 % was more than offset by a volume decline of 6.7 % due to the Middle East conflict. Sales grew at a double-digit percentage rate in Specialties, while Propylene recorded a low-single-digit level decline, and a double-digit percentage rate decline in Ethylene and Syngas and Fuels.

EBITDA Margin

In the third quarter, EBITDA before exceptional items decreased by 29.4 % to CHF 23.1 million, representing a margin of 13.3 % versus 19.1 % in the prior year. This was driven by lower volumes as high-margin customer orders shifted due to the Middle East conflict, which negatively impacted operating leverage. A less favorable business mix and a negative inventory valuation effect further weighed on the margin.

Reported EBITDA of CHF 23.3 million decreased by 28.3 % compared to the prior year, with a corresponding margin of 13.4 % versus 19.0 %.

EBITDA margin before exceptional items for the first nine months of 2026 decreased to 14.0 % from 19.5 % in the prior year. Reported EBITDA decreased by 39.3 % to CHF 63.2 million from CHF 104.1 million, with the corresponding margin decreasing by 610 basis points to 12.8 % from 18.9 %.

Based on a strong order book, the Catalysts business is expected to deliver a robust final quarter of the year.

Business Unit Adsorbents & Additives

Third Quarter					First Nine Months
in CHF million	2026	2025	% CHF	% LC(1)	2026	2025	% CHF	% LC(1)
Sales	263.7	244.3	7.9	6.4	753.9	749.0	0.7	3.0
EBITDA	41.8	42.7	– 2.1		129.1	126.4	2.1
– margin	15.9 %	17.5 %			17.1 %	16.9 %
EBITDA before exceptional items	48.9	42.5	15.1		142.7	139.9	2.0
– margin	18.5 %	17.4 %			18.9 %	18.7 %
Sales bridge:	Price 5.4 %; Volume 1.0 %; Scope 0 %; Currency 1.5 %				Price 2.8 %; Volume 0.2 %; Scope 0 %; Currency – 2.3 %

⁽¹⁾ Excluding hyperinflation accounting country Türkiye

Sales

In the third quarter of 2026, sales in the Business Unit Adsorbents & Additives increased by 6.4 % in local currency and by 7.9 % in Swiss francs. Sales were slightly higher in the Adsorbents segments, while Additives’ sales grew strongly at a double-digit percentage rate. For the business unit, pricing was up 5.4 %, while volumes increased by 1.0 %, driven by Polymer Solutions, Coatings & Adhesive and Adsorbents Americas offsetting lower volumes in Adsorbents EMEA and APAC.

In Europe, Middle East & Africa, the largest region, sales grew at a mid-single-digit percentage rate, as strong growth in Additives more than offset lower demand in industrial segments for Adsorbents. In the Americas, sales increased at a double-digit percentage rate, driven by Additives and supported by Adsorbents as the recovery of biofuel purification continued. Asia-Pacific sales increased at a low-single-digit percentage rate, driven by growth in Additives, offsetting lower demand in Adsorbents.

In the first nine months of 2026, sales in the Business Unit Adsorbents & Additives increased by 3.0 % in local currency and by 0.7 % in Swiss francs, as strong growth in Additives more than offset softer demand in Adsorbents. Positive pricing of 2.8 % was supported by resilient volumes of 0.2 %.

EBITDA Margin

In the third quarter, EBITDA before exceptional items increased by 15.1 % to CHF 48.9 million, representing a margin of 18.5 %, which was 110-basis-points higher compared to the 17.4 % margin in the prior year. The improvement was driven by positive mix effects, active margin management and contribution from performance improvement programs.

Reported EBITDA of CHF 41.8 million decreased by 2.1 % compared to the prior year, while the corresponding margin of 15.9 % represents a 160-basis-point decline from 17.5 % in the third quarter of 2025 as a result of higher restructuring charges compared to the prior year.

EBITDA margin before exceptional items for the first nine months of 2026 increased by 20 basis points to 18.9 % from 18.7 % in the prior year. Reported EBITDA increased to CHF 129.1 million from CHF 126.4 million, with the corresponding margin increasing by 20 basis points to 17.1 % from 16.9 %.

Q3 / 9M 2026 Media Release

CORPORATE MEDIA RELATIONS Jochen Dubiel Phone +41 61 469 63 63 jochen.dubiel@clariant.com Luca Lavina Phone +41 61 469 63 63 luca.lavina@clariant.com Charlène Obrietan Phone +41 61 469 63 63 charlene.obrietan@clariant.com Follow us on X, Facebook, LinkedIn, Instagram.

INVESTOR RELATIONS Andreas Schwarzwälder Phone +41 61 469 63 73 andreas.schwarzwaelder@clariant.com Thijs Bouwens Phone +41 61 469 63 73 thijs.bouwens@clariant.com

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials. www.clariant.com Clariant is a focused specialty chemical company led by the overarching purpose of “Greater chemistry – between people and planet.” By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On 31 December 2025, Clariant totaled a staff number of 10 281 and recorded sales of CHF 3.915 billion in the fiscal year. Since January 2023, the Group conducts its business through the three Business Units Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.

• Disposals Retail Park De Mael and Eggert will reduce loan-to-value (LTV) by 250bps
• Net Debt/EBITDA among the strongest in the industry: 7.1x post disposals
• Accelerated growth in quarterly Direct result per share (DRPS), up to € 0.49 in Q3 from € 0.46 in Q2
• Strong operational results: positive Dutch leasing spread, stable occupancy and 99% rent collection
• Key lease renewals signed with fuel and service retailer Q8 for our two centers in Luxembourg
• € 60m in new credit facilities in Belgium
• New Dutch structure to support efficient capital recycling and contribute positively to DRPS 2027
• Forecast FY 2026 DRPS confirmed at € 1.85-1.95

Attachment

• Wereldhave_Trading-update-Q3-2026

Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO™/JERAYGO™ (aprocitentan).

Date:         Wednesday, November 4, 2026
Time:         14:00 CET / 13:00 GMT / 08:00 ET

The call will start with presentations by senior management, followed by a Q&A session.

Live Webcast (audio + slides):
The live webcast can be accessed from the Idorsia website www.idorsia.com.

Dial-in procedure for analysts (audio only):
Analysts who would like to ask questions are required to register in advance of the conference using the following link:
https://register-conf.media-server.com/register/BIb4064ef7afb34b7f9986e4be59fbf2ba

Replay: A replay of the investor webcast will be available through www.idorsia.com approximately 60 minutes after the call has ended.

More upcoming events

• Octavian QuickBite Lunch in Zurich on Nov 3, 2026.
• Guggenheim Healthcare Innovation Conference in Boston on Nov 9, 2026.
  • Fireside chat at 8:30am ET. Link to live audio stream: https://event.summitcast.com/view/oVDtKqmPn2tPc7VV7WsLAC/iw8SwuYjiQ2o9QGD9edwea
• Stifel Healthcare Conference in New York on Nov 11, 2026.
• UBS Global Biopharma Conference in London on Nov 16, 2026.
• Jefferies Global Healthcare Conference in London on Nov 17, 2026.
• Evercore Healthcare Conference in Miami on Nov 30, 2026.
• Citi Global Healthcare Conference in Miami on Dec 2, 2026.
• Deutsche Bank C-Suite call series on Dec 10, 2026.
• J.P. Morgan 2027 Healthcare Conference in San Francisco, Jan 11-14, 2027.
• Octavian Seminar in Davos on Jan 15, 2027.
• Full-year 2026 Financial Results reporting on February 25, 2027.
• First quarter 2027 Financial Results reporting on April 29, 2027.
• Annual General Meeting of Shareholders 2027 on May 13, 2027.

Notes to the editor

About Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact
Kevin Boss
Director, Investor Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the latest Financial Report.

Attachment

• Press Release PDF

 Paris, 03 November 2026, 07:00am

  

• Strong Q3 2026, with sustained volume growth and margin expansion across Energy Distribution activities
• Energy Distribution: sustained volume growth in Retail & Marketing (+7%), underpinned by strong growth in bitumen (+82% yoy, +15% excl. Europe). Improved fuel unit margin in East Africa
• Renewable Electricity Production: Accelerating expansion with secured portfolio up +20% vs Sept-25 at 1.5 GWp. Successful farm-down of Photosol’s flagship Creil solar farm

SALES BREAKDOWN BY SEGMENT AND BY REGION

As a reminder, in the Energy Distribution business, Rubis passes on changes in oil price to customers. Thus, key indicators to analyse performance are volume and unit margin (see tables below) rather than revenue.

	Q3 2026	Q3 2025	Q3 2026 vs Q3 2025
Volume distributed (in ‘000 m3)	1,737	1,622	+7%
Revenue (in €m) Energy Distribution	2,246	1,560	+44%
Retail & Marketing	1,919	1,345	+43%
Europe	261	197	+33%
Caribbean	748	556	+35%
Africa	909	592	+54%
Support & Services	327	215	+52%
Renewable Electricity Production	29	21	+40%
TOTAL	2,275	1,580	+44%

On 3 November 2026, Clarisse Gobin-Swiecznik, Jean-Christian Bergeron and Marc Jacquot, Managing Partners, commented: “Rubis delivered another solid quarter, reflecting the strength of its diversified energy platform and the disciplined execution across geographies and business lines. In Energy Distribution, commercial momentum remained robust, supported by the quality of our asset base and our ability to capture growth opportunities in our markets. At Photosol, the opening of the capital of the Creil solar park to Banque des Territoires marks an important milestone, validating both the quality of our assets and the attractiveness of our development model. We have also taken a significant step forward with the proposed conversion of Rubis into a Société Anonyme, a project designed to strengthen our governance framework, enhance our market profile and support the Group’s long-term development ambitions. Given our year-to-date performance and outlook for the rest of the year, we reaffirm our EBITDA guidance for 2026.”

HIGHLIGHTS

Proposal to convert the Group into a French limited company (Société Anonyme)

On 19 October 2026, Rubis announced a proposal to convert the Group into a French limited company (Société Anonyme) with a Management Board (Directoire) and a Supervisory Board.

The Group Management Board (Directoire) would be composed of Jean-Christian Bergeron proposed as Chairman of the Management Board, alongside Marc Jacquot (Finance, IT & Renewables) and Fred Royer (Bitumen & Business Development). The Supervisory Board would retain its 11 current members and be expanded to include Jacques Riou and Clarisse Gobin-Swiecznik; Marc-Olivier Laurent would remain Chairman.

Completion of the conversion remains subject to the Autorité des marchés financiers (AMF) issuing a decision confirming that no mandatory tender offer (offre publique de retrait) is required, and to approval by Rubis’ shareholders at a Shareholders’ Meeting expected to be held on 9 December 2026¹.

First farm-down of a flagship solar asset to a long-term institutional partner

During Q3 2026, Photosol completed the farm-down of its flagship Creil solar park to Banque des Territoires (Groupe CDC), which acquired a 49% interest in the project. The transaction crystallises value from a significant asset and illustrates Photosol’s ability to attract leading long-term infrastructure investors.

Q3 & 9M 2026 COMMERCIAL PERFORMANCE

1. ENERGY DISTRIBUTION – RETAIL & MARKETING

Volume sold and gross margin by product in Q3 2026

	Volume (in ‘000 m3)			Gross margin (in €m)
	Q3 2026	Q3 2025(1)	Q3 2026 vs Q3 2025	Q3 2026	Q3 2025(2)	Q3 2026 vs Q3 2025
LPG	352	352	0%	76	75	+1%
Fuel	1,182	1,158	+2%	129	114	+13%
Bitumen	203	112	+82%	23	18	+29%
TOTAL	1,737	1,622	+7%	228	207	+10%

(1) Including unbranded LPG in Europe and Africa for 41,000 m³.
(2) Including unbranded LPG in Europe and Africa for €1m.

Volume sold and gross margin by region in Q3 2026

	Volume (in ‘000 m3)			Gross margin (in €m)
	Q3 2026	Q3 2025(1)	Q3 2026 vs Q3 2025	Q3 2026	Q3 2025(2)	Q3 2026 vs Q3 2025
Europe	299	231	+30%	54	52	+3%
Caribbean	651	612	+6%	91	82	+10%
Africa	787	779	+1%	84	72	+16%
TOTAL	1,737	1,622	+7%	228	207	+10%

(1) Including unbranded LPG in Europe and Africa for 41,000 m³.
(2) Including unbranded LPG in Europe and Africa for €1m.

As was anticipated, Q3 2026 was a quarter of strong volume growth for bitumen, and growth normalisation in fuel and LPG, combined with an increase in unit margin on fuel.

LPG volumes remained stable in Q3 2026. Strong growth in autogas, particularly in France and Spain, and positive momentum in South Africa, Morocco and the Caribbean offset lower bulk volumes and softer activity in some European markets. Gross margin increased by +1%, supported by a favourable business mix.

As regards fuel:

• The retail business (service stations representing 51% of Q3 fuel volume and 56% of fuel gross margin) performed well. Total volume grew by +1.3% in Q3 2026 vs Q3 2025 and gross margin by +15% over the same period. Retail volumes were supported by strong commercial momentum in Haiti and Kenya. Gross margin also benefited from the continued recovery in Haiti and from higher unit margins in East Africa following the adjustment to the pricing formula. This positive performance was partly offset by a sharp decline in Corsica, where the price gap resulting from a competitor’s fuel price cap continued to weigh on both volumes and margins, particularly during the summer season.
• The Commercial and Industrial business (C&I, representing 34% of Q3 fuel volume and 27% of fuel gross margin) increased by +4% in volume in Q3 2026 vs Q3 2025 and gross margin increased by +3%. Momentum was strong in the Caribbean, particularly in Haiti and Suriname. Haiti continued to benefit from the recovery in activity initiated in 2025. These favourable trends largely offset softer activity in Africa. Gross margin also improved, supported by the favourable contribution of Caribbean operations.
• The aviation segment (representing 15% of Q3 fuel volume and 15% of fuel gross margin) was down -1% in volume, and up +25% in gross margin, thereby improving unit margin by +26%. The pressure on the Kenyan aviation business continues. However, Aviation volumes continued to benefit from solid traffic levels across the Caribbean, supported by strong performances in Saint Lucia and Barbados.
• The lubricants segment (representing 0.4% of fuel volume and 2.6% of fuel gross margin) was up +19% in volume and +42% in gross margin. Lubricants activity delivered strong growth in both volumes and gross margin, driven by Kenya and supported by Uganda and Ethiopia. The performance reflected strong commercial momentum, higher export sales and continued progress in premium lubricant market penetration.

Bitumen delivered strong volume growth (+82% yoy and +15% excl. Europe) and margin growth (+29% and +11% excl. Europe). Bitumen activity delivered another strong quarter. In Africa, growth was driven by sustained infrastructure demand across several markets, notably South Africa, where Rubis achieved near-record sales levels, and Gabon, where activity continued to benefit from major road projects. Cameroon and Angola also delivered strong performances supported by ongoing infrastructure developments and new projects. In Europe, the Group’s North-West European platform continued to ramp up in line with plan, supported by growing export activity and favourable market conditions.

2. ENERGY DISTRIBUTION – SUPPORT & SERVICES

The Support & Services activity recorded €327m of revenue (+52% yoy) in Q3 2026, reflecting increased oil prices.

Trading for third parties volume excluding crude deliveries was lower at -7% in Q3 2026 vs Q3 2025 as bitumen vessels were utilised at a higher level for in-house deliveries. However, margins were stable over the same period.

SARA refinery and logistics operations present specific business models with stable earnings profile which can generate some volatility on revenue from quarter to quarter.

3. RENEWABLE ELECTRICITY PRODUCTION – PHOTOSOL

Operational data	Q3 2026	Q3 2025	Var %
Assets in operation (MWp)	805	633	+27%
Electricity production (GWh)	286	197	+45%
Revenue (in €m)	29	21	+40%

Over Q3 2026, Photosol installed 6 MWp, leading its assets in operation to reach 805 MWp (+27% yoy). The secured portfolio increased by +20% yoy to 1.5 GWp. The pipeline reached 5.6 GWp down -5% yoy. Revenue for Q3 2026 stood at €29m, up 40% vs Q3 2025 reflecting portfolio expansion.

OUTLOOK

Group EBITDA guidance is reaffirmed at €775m to €825m in 2026 at constant EUR/USD exchange rate (1.13) and assuming IAS 29 – hyperinflation impact unchanged vs 2025.

As a reminder, the impacts of IAS 29 – hyperinflation accounting treatment on FY 2025 amounted to €8m on EBITDA, €4m on EBIT and -€13m on Net income Group Share.

NON-FINANCIAL RATING

• MSCI: AA (reiterated in Dec-25)
• Sustainalytics: 32.2 (from 29.2 previously)
• ISS ESG: C+ (from C previously)
• CDP: A- (from B previously)

Conference for investors and analysts
Date: 03 November 2026, 9:30am
To access the audio webcast: https://rubis.engagestream.euronext.com/q3_9m_trading_update_2026/register
Participants from Rubis:

• Marc Jacquot, Managing Partner & Group CFO
• Clémence Mignot-Dupeyrot, Head of IR

Upcoming events
Combined Shareholders’ Meeting: 09 December 2026
Q4 & FY 2026 Results: 11 March 2027

   

Press Contact	Analyst Contact
RUBIS – Communication Department	RUBIS – Clémence Mignot-Dupeyrot, Head of IR
Tel: +33 (0)1 44 17 95 95 presse@rubis.fr	Tel: +33 (0)1 45 01 87 44 investors@rubis.fr

appendix

1. 9M REVENUE BREAKDOWN

Revenue (in €m)	9M 2026	9M 2025	9M 2026 vs 9M 2025
Energy Distribution	6,276	4,803	+31%
Retail & Marketing	5,415	4,103	+32%
Europe	750	604	+24%
Caribbean	2,069	1,692	+22%
Africa	2,596	1,808	+44%
Support & Services	861	700	+23%
Renewable Electricity Production	66	52	+28%
TOTAL	6,342	4,855	+31%

2. 9M FIGURES

RETAIL & MARKETING: VOLUME SOLD AND GROSS MARGIN BY PRODUCT IN 9M 2026

	Volume (in ‘000 m3)			Gross margin (in €m)
	9M 2026	9M 2025(1)	9M 2026 vs 9M 2025	9M 2026	9M 2025(2)	9M 2026 vs 9M 2025
LPG	1,099	1,091	+1%	254	239	+6%
Fuel	3,496	3,333	+5%	378	334	+13%
Bitumen	618	400	+55%	93	63	+47%
TOTAL	5,212	4,825	+8%	725	636	+14%

(1) Including unbranded LPG in Europe and Africa for 109,000 m³.
(2) Including unbranded LPG in Europe and Africa for €4m.

RETAIL & MARKETING: VOLUME SOLD AND GROSS MARGIN BY REGION IN 9M 2026

	Volume (in ‘000 m3)			Gross margin (in €m)
	9M 2026	9M 2025(1)	9M 2026 vs 9M 2025	9M 2026	9M 2025(2)	9M 2026 vs 9M 2025
Europe	905	733	+24%	190	175	+9%
Caribbean	1,969	1,807	+9%	267	250	+7%
Africa	2,339	2,285	+2%	268	212	+26%
TOTAL	5,212	4,825	+8%	725	636	+14%

(1) Including unbranded LPG in Europe and Africa for 109,000 m³.
(2) Including unbranded LPG in Europe and Africa for €4m.

---

¹ Subject to obtaining a final AMF decision that is no longer subject to appeal.

Attachment

• PR_Rubis Q3 9M 2026 trading update Press Release

  

Consolidated revenue of $17 million, representing 55% year-over-year growth; reaffirms FY 2026 revenue guidance of 50% to 100% year-over-year growth

Subsequent WISeSat.Space Nasdaq listing establishes dedicated public-market platform for secure satellite connectivity

Geneva, Switzerland – November 3, 2026 – Ad hoc announcement pursuant to Art. 53 LR – WISeQey Corp. (formerly known as WISeKey International Holding AG, “WISeQey”, the “Company” or the “Group”) (Nasdaq/SIX: WQEY), a global quantum cybersecurity and space IoT company, today announced its preliminary unaudited financial metrics for the nine-month period ended September 30, 2026 (“9M 2026”), provided an update on corporate developments, and reaffirmed its full-year 2026 revenue guidance.

9M 2026 Key Financial Metrics

• Revenue growth of 55%: Preliminary unaudited 9M 2026 revenue of $17 million, compared to $11 million in 9M 2025.
• Strong liquidity: Group consolidated cash, cash equivalents and restricted cash of approximately $471.0 million at September 30, 2026.
• Subsidiary SEALSQ’s post-quantum pipeline exceeds $100 million: An active, evolving business pipeline of more than $200 million through 2029 as of October 15, 2026, including more than $100 million associated with Post-Quantum projects, including the QS7001 and QVault TPM.  These figures represent management estimates of potential opportunities and are subject to risks such as conversion risk, customer validation, technical integration and other commercial risks.

Revenue Drivers
The 9M 2026 increase was driven primarily by growth in the Group’s subsidiary, SEALSQ Corp (“SEALSQ”):

• Continued strong demand for SEALSQ’s Vault-IC secure-element family across industrial, smart-energy IoT and P25 Radio protocol application deployments.
• Growth in recurring PKI subscriptions, certificate-management and digital identity services.
• Nine months of consolidated revenue from IC’Alps SAS, which contributed approximately $3.8 million in 9M 2026 through custom ASIC design and secure semiconductor engineering services.
• Ramp-up of the Quantix Edge Security sovereign semiconductor design and personalization center in Murcia, Spain.
• Initial sampling and evaluation revenue from QS7001 and QVault TPM as 42 customers are now evaluating the next generation of secure semiconductor products.

FY 2026 Revenue Outlook
WISeQey’s outlook statements are based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.  WISeQey reaffirms its FY 2026 revenue growth guidance of approximately 50% to 100%, representing a range of approximately $27 million to $36 million, compared with audited FY 2025 revenue of $19 million.

The Company expects a more significant contribution from its subsidiary SEALSQ’s post-quantum product lines in 2027 and beyond as customers complete technical integration and move into volume production. Timing remains subject to laboratory review, certification, customer qualification and procurement.

Carlos Moreira, Founder, Chairman and Chief Executive Officer of WISeQey, commented: “Our focus is converting our technology portfolio into customer deployments and sustainable commercial growth. SEALSQ’s revenue progress, together with WISeSat.Space Holdings Corp.’s (NASDAQ: SAIQ) (“WISeSat.Space”) subsequent Nasdaq listing, strengthens the foundations for the next stage of our development. We are connecting hardware security, trusted identities and satellite communications to address the needs of increasingly intelligent and autonomous systems. Our priorities remain on execution, converting commercial opportunities into customer deployments, allocating capital with discipline and building sustainable value for WISeQey shareholders.”

Corporate Developments
During January – October 2026, WISeQey’s announcements focused on digital identity, post-quantum semiconductors, quantum computing and secure satellite infrastructure, alongside corporate restructuring and preparations for subsidiary listings.

• WISeQey corporate transition. On October 5, 2026, following its cross-border merger and redomiciliation, WISeQey began trading on Nasdaq and SIX under the symbol WQEY.
• WISeSat.Space listing and ownership. On October 1, 2026, WISeSat.Space completed its combination with Columbus Acquisition Corp. and commenced trading on the Nasdaq under the symbol SAIQ on October 2, 2026.  WISeQey remains the ultimate parent company of WISeSat.Space and directly holds 23,387,061 WISeSat.Space shares, including 11,430,139 Ordinary Shares and 11,956,922 Class F shares. WISeQey’s subsidiary, SEALSQ Corp, holds 3,018,294 shares, split between 1,977,816 Ordinary Shares and 1,040,478 Class F Shares.  This brings WISeQey’s reported aggregate beneficial ownership totals to 26,405,355 shares, approximately 88.5% of the ordinary-share class on an as-converted basis.
• Expansion of the SEALQuantum Sovereign Vertical Stack. Through SEALSQ, the Group completed the acquisition of Miraex, invested approximately €15 million in Quobly, increased its total EeroQ investment to $7 million and made a majority investment in Wecan. This is a strategic quantum initiative through which the Group allocates its own capital across quantum and post-quantum technologies with the aim to develop a Sovereign Quantum Vertical Stack.
• Creation of Quantisimo. In June, WISeKey and SEALSQ established Quantisimo Corp. and announced a non-binding LOI with GigCapital8 regarding a Nasdaq-listed pure-play quantum platform. On October 9, 2026, WISeQey and SEALSQ entered into a definitive merger agreement with GigCapital8, Quantisimo and Quantisimo Holdings Corp. (“PubCo”), under which Quantisimo and GigCapital8 will become wholly owned subsidiaries of PubCo, which is expected to list on the Nasdaq Capital Market. Prior to closing, WISeQey and SEALSQ will contribute to Quantisimo certain of their equity interests in Miraex, SEALCOIN, Wecan and WISeSat.Space. Upon closing, WISeQey and SEALSQ will receive an aggregate of 66,610,000 shares of the new publicly listed holding company, Quantisimo Holding Corp. (“PubCo”), implying a pro forma equity value for Quantisimo of approximately $666.1 million at $10.00 per share, and are expected to hold a majority of PubCo’s outstanding ordinary shares.   Closing is subject to, among other conditions, available cash of at least $15 million, approval by GigCapital8’s shareholders, regulatory approvals, effectiveness of a registration statement on Form F-4, Nasdaq listing approval, and there can be no assurance that it will be completed on the contemplated terms or at all. The Group continues to target completion during the first quarter of 2027.
• Satellite infrastructure and international partnerships. WISeSat.Space announced completion of a Swiss Space Command pilot phase in April and the planned development of the Quantum Spatial Orbital Cloud in conjunction with SEALSQ. On October 20, 2026, WISeSat.Space confirmed the successful launch and deployment of FOSSASAT-2E27, a new-generation 6U satellite developed and operated by its longstanding strategic partner FOSSA Systems (“FOSSA”), aboard SpaceX’s Falcon 9 Bandwagon-5 mission. The partnership, supported by successive investments, aims to validate the technology across up to six satellite missions amid expectations of accelerating demand for quantum-resistant security. The collaboration is expected to support the progressive validation of VaultIC secure elements and, subject to technical readiness and integration, the next-generation QS7001 post-quantum secure element.
• Post-quantum commercialization. SEALSQ advanced validation and customer sampling of its QS7001 and QVault TPM products. Its estimated commercial pipeline as of October 15, 2026 exceeded $200 million through 2029, including more than $100 million associated with post-quantum projects. These represented potential opportunities, rather than combined revenues, and remain subject to conversion into revenue.

Digital identity and the machine economy. In June 2026, WISeQey’s SEALCOIN subsidiary announced a $4 million investment commitment supporting SEALCOIN infrastructure, including a $1 million commitment from The Hashgraph Group (“THG”), with the object to accelerate the integration of the SEALCOIN ecosystem into the rapidly emerging space economy. In addition, WISeQey is targeting further integration of WISeID into Wecan’s compliance solutions and participation in Hedera’s strategic and community partner network.

• Swiss infrastructure. In September, the Group announced the signature of a memorandum of understanding with the Canton of Jura for the establishment of a post-quantum semiconductor and cybersecurity center in the Canton of Jura. The proposed Jura Center represents an indicative public-private investment of approximately CHF 40-60 million over a period of approximately six years and is intended to establish a strategic Swiss capability for the design, personalization, testing and secure provisioning of next-generation post-quantum semiconductor technologies.

Strategy and Outlook
WISeQey aims to integrate secure semiconductors, digital identity, satellite connectivity, AI and machine transactions into trusted infrastructure. Following its successful direct listing on the Nasdaq, WISeQey is aiming to stay ahead of the ever-evolving technology landscape as we enter the Intelligence Age, an era in which billions of intelligent machines will communicate, learn, make decisions, and increasingly act on their own. Electric vehicles will communicate with infrastructure, robots will work with humans and other robots, drones will navigate on their own, and satellites will connect machines across the planet. As these systems become autonomous, they will all need one fundamental thing: trust. WISeQey is building that trusted infrastructure by combining secure semiconductors, digital identity, post-quantum cybersecurity, AI, IoT, and secure satellite communications.

About WISeQey

WISeQey Corp. (“WISeQey”) is a British Virgin Islands holding company focused on post-quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat.Space (Nasdaq: SAIQ) develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeQey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, FY 2026 revenue guidance, business pipeline, the timing of commercial adoption of post-quantum products, the anticipated benefits of acquisitions, investments and listings, the proposed Quantisimo business combination, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Words such as “aims,” “ambition,” “anticipates,” “estimates,” “expects,” “guidance,” “intends,” “pipeline,” “plans,” “targets,” “will” and similar expressions are intended to identify forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include WISeQey’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; WISeQey’s dependence on the results of its subsidiary SEALSQ Corp for a majority of its consolidated revenue and earnings; adjustments to preliminary unaudited 9M 2026 financial information upon completion of financial closing and review procedures; the ability to achieve FY 2026 revenue guidance; the conversion of the estimated business pipeline into revenue, which depends on customer validation, technical integration and other commercial factors; the timing and outcome of laboratory review, certification, customer qualification and procurement for the QS7001, QVault TPM and other post-quantum products; the ability to integrate acquired businesses, including IC’Alps SAS, Miraex and Wecan, and to realize value from the SEALQuantum Sovereign Vertical Stack; the effects of WISeQey’s cross-border merger and redomiciliation; the trading performance of, and WISeQey’s ownership in, WISeSat.Space following its combination with Columbus Acquisition Corp.; the risks of satellite launches and missions; the risk that the proposed Quantisimo business combination with GigCapital8 is not completed by March 31, 2027 or at all, including as a result of a failure to obtain the approval of GigCapital8’s shareholders or required regulatory approvals, the registration statement on Form F-4 not becoming effective, Nasdaq listing approval not being obtained, the minimum cash condition not being satisfied, including as a result of redemptions by GigCapital8’s shareholders, or the termination of the merger agreement; the amount of cash SEALSQ may be required to contribute in connection with the proposed Quantisimo business combination; the effect of contributing the Group’s interests in Miraex, SEALCOIN, Wecan and WISeSat.Space to Quantisimo, and the value and trading performance of PubCo shares received by WISeQey and SEALSQ; whether the memorandum of understanding with the Canton of Jura leads to definitive agreements and the anticipated investment; and other risks described in WISeQey’s filings with the U.S. Securities and Exchange Commission. WISeQey is providing this communication as of this date and does not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

Statements regarding our business pipeline are based on management’s current estimates of potential revenue opportunities and do not represent backlog or contracted revenue. Pipeline conversion is subject to numerous factors including customer validation, technical integration requirements, certification timelines, and market conditions. There can be no assurance that pipeline opportunities will convert to actual sales or that such conversion will occur within anticipated timeframes.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeQey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeQey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Additional Information About the Proposed Quantisimo Business Combination and Where to Find It
In connection with the proposed business combination among Quantisimo Corp., GigCapital8 Corp. (“GigCapital8”) and the other parties thereto (the “Proposed Business Combination”), GigCapital8 and Quantisimo Holdings Corp. intend to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4, which will include a preliminary proxy statement of GigCapital8 and a prospectus. After the registration statement is declared effective, a definitive proxy statement/prospectus will be mailed to GigCapital8’s shareholders as of a record date to be established for voting on the Proposed Business Combination. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION. Investors and security holders will be able to obtain free copies of these documents, once available, at the SEC’s website at www.sec.gov.

Participants in the Solicitation
WISeQey, SEALSQ, Quantisimo Corp., GigCapital8 and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from GigCapital8’s shareholders in connection with the Proposed Business Combination. Information regarding the names and interests of these persons in the Proposed Business Combination will be set forth in the proxy statement/prospectus and other relevant materials filed with the SEC when they become available.

No Offer or Solicitation
This press release is for informational purposes only and does not constitute a proxy statement or a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination, and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Press and Investor Contacts

WISeQey Corp. Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeQey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

November 3, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November:

• Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m. ET in Boston, MA.
• Jefferies London Global Healthcare Conference. Fireside chat on Tuesday, November 17 at 8:30 a.m. GMT in London, UK.

A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

November 3, 2026

Q3 2026 Group performance

• Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment
• Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth
• Income from operations of EUR 165 million
• Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments
• Operating cash flow of EUR 544 million; free cash flow of EUR 384 million
• Respironics reached agreement in principle with the US Department of Justice
• Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:
“We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.

We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.

Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people.”

Group and segment performance

Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.

Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.

Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

Innovation highlights

• Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.
• The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.
• Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips’ Capsule platform, and supports future technology needs.
• Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.
• Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico’s largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.
• Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips’ diagnostic imaging and image-guided therapy capabilities with Asia Medical Group’s cardiovascular expertise.
• Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent’s first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.

Productivity

Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.

Progress on Respironics-related legal proceedings

Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.

Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.

Outlook

Philips reiterates its full-year 2026 outlook:

• Comparable sales growth: 3%-4.5%
• Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%
• Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million

Within the context of an uncertain macro-environment, Philips’ 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.

Capital allocation

In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note program. The Notes are the healthcare industry’s first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips’ current debt structure.

Further information: conference call, video webcast and website

Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.

Click here to view the release online

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include, but are not limited to, macro-economic and geopolitical changes – including the war in Ukraine and ongoing tensions in the Middle East – as well as measures such as enacted and proposed tariffs and trade actions introduced in response to rising global tensions; Philips’ ability to keep pace with the changing health technology environment; Philips’ ability to gain leadership in artificial intelligence and health informatics in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2025.

Third-party market share data

Statements regarding market share contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management’s estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2025.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2025. Certain prior year balances have been reclassified to conform to the current period presentation.

* Non-IFRS financial measure. Refer to the Reconciliation of non-IFRS information